Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

AIDS

Volumn 11, Issue 15, 1997, Pages

  Merry, Concepta ^a,b   Barry, Michael G ^a   Mulcahy, Fiona ^b   Halifax, Kathryn L ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Saquinavir pharmacokinetics; Saquinavir nelfinavir interaction

Indexed keywords

ANTIVIRUS AGENT; NELFINAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

EID: 0030830568     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199715000-00001     Document Type: Article

References (17)

1. BHIVA Guidelines Co-ordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
2. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 348:1408-1409.
3. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
4. Moyle G: Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996, 5:155-167.
5. Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997, 32:194-209.
6. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
7. Fitzsimmons ME, Collins JM: Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4. Drug Metab Dispos 1997, 25:256-266.
8. Washington CB, Duran GE, Sikic BI, Blaschke TF: Saquinavir is a high affinity substrate for the multidrug transporter, P-glycoprotein [abstract]. Clin Pharmacol Ther 1997, 61:193.
9. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
10. Kumar GN, Rodrigues D, Buko AM, Denisson JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996, 277:423-431.
11. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. A review for clinicians. J Am Med Assoc 1997, 277:145-153.
12. Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997, 44: 190-194.
13. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
14. Perry CM, Benfield P: Nelfinavir. Drugs 1997, 54:81-87.
15. Kravcik S, Sahai J, Kerr B, et al.: Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 389].
16. Sahai J: Risks and synergies from drug interactions. AIDS 1996, 10 (suppl 1):S21-S25.
17. Cameron DW, Hsu A, Granneman GR, et al.: Pharmacokinetics of ritonavir-saquinavir combination therapy [abstract]. AIDS 1996, 10 (suppl 2):S16.